Dyne Therapeutics joined PPMD for a community webinar on Wednesday, July 20, 2022. Dyne provided an update on the recent U.S. Food and Drug Administration (FDA) announcement lifting the DYNE-251 clinical hold and clearing the Investigational New Drug (IND) application. Dyne will initiate a clinical trial of DYNE-251 in individuals with Duchenne amenable to skipping exon 51 and expects to begin dosing trial participants in mid-2022.

If you missed the live event, the recording can be found below.

 

Watch the Recording